10x Genomics, Inc.
10x Genomics, Inc. (TXG) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
txg · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for 10x Genomics, Inc. (TXG) measures how much investors pay for each dollar of the company's trailing earnings. TXG's current PE ratio of N/A is calculated by dividing its stock price of $29.34 by its TTM earnings per share of -$0.18.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2017 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Medical - Healthcare Information Services · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
10x Genomics, Inc.You TXG | $3.7B | N/A | — | -$0.18 |
 Certara, Inc. CERT | $824M | N/A | — | -$0.01 |
 Guardian Pharmacy Services, Inc. GRDN | $2.6B | 38.14x | -92.8% | $0.79 |
 Janux Therapeutics, Inc. JANX | $821M | N/A | — | -$1.83 |
 Nuvation Bio Inc. NUVB | $1.7B | N/A | — | -$0.60 |
 Omnicell, Inc. OMCL | $1.9B | 1014.72x | +92.8% | $0.04 |
 Omada Health OMDA | $1.1B | N/A | — | -$0.22 |
Industry Average 2 peers with valid PE | — | 526.43x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-0.35 | — | |
2024-12-31 FY2024 | — | $-1.52 | — | |
2023-12-31 FY2023 | — | $-2.18 | — | |
2022-12-31 FY2022 | — | $-1.46 | — | |
2021-12-31 FY2021 | — | $-0.53 | — | |
2020-12-31 FY2020 | — | $-5.37 | — | |
2019-12-31 FY2019 | — | $-0.80 | — | |
2018-12-31 FY2018 | — | $-8.40 | — | |
2017-12-31 FY2017 | — | $-1.62 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for 10x Genomics, Inc. (TXG) measures how much investors pay for each dollar of the company's trailing earnings. TXG's current PE ratio of N/A is calculated by dividing its stock price of $29.34 by its TTM earnings per share of -$0.18.
Frequently asked questions
TXG pe ratio · 6 questionsTXG's current PE ratio is N/A as of 2026-06-08, based on a stock price of $29.34 and TTM EPS of -$0.18. Data sourced from Financial Modeling Prep via TXG's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · 10x Genomics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08